We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
ZeptoMetrix an Antylia scientific company

Download Mobile App




Risk for Colorectal Cancer Linked to Polyps and Adenomas

By LabMedica International staff writers
Posted on 25 Oct 2017
Most colorectal cancer develops from precursors known as polyps, the most common of which are conventional adenomas. More...
Conventional adenomas often progress to colorectal cancer through an intermediate step called high-risk adenomas.

Another type of polyp known as serrated polyps may proceed up to 15% of colorectal cancer. Serrated polyps may occur in up to 20% of all adults over 50 years of age, however, when it comes to progression to colorectal cancer, less is known about serrated polyps than conventional adenomas.

Scientists at the Dartmouth-Hitchcock Medical Center (Lebanon, NH, USA) collected data from a population-based colonoscopy registry that has been collecting and analyzing data on colonoscopies across the state of New Hampshire since 2004, including rates of adenoma and serrated polyp detection. Patients completed a questionnaire to determine demographic characteristics, health history, and risk factors for colorectal cancer (CRC), and were followed from index colonoscopy through all subsequent surveillance colonoscopies. The analyses included 5,433 participants (median age 61 years; 49.7% male) with two colonoscopies (median time to surveillance, 4.9 years).

Each index risk group, were assessed for size and by histology. Two analyses were performed. The primary analysis compared 817 participants with high-risk adenoma (HRA) with or without synchronous serrated polyps (SP) and those 3,198 with no adenoma with or without synchronous serrated polyps at index colonoscopy. The secondary analysis included 1,418 participants with low risk adenoma (LRA) with and without synchronous serrated polyps and those 3,198 with no adenoma with and without serrated polyps at index colonoscopy.

The investigators found that HRA and synchronous large SP (odds ratio [OR] = 5.61), HRA with synchronous traditional serrated adenomas (STSA) (OR = 16.04), and HRA alone (OR = 3.86) at index colonoscopy significantly increased the risk of metachronous HRA compared to the reference group (no index adenomas or serrated polyps). Large index SPs alone (OR=14.34) or index STSA alone (OR = 9.70) significantly increased the risk of a large metachronous SP.

The authors concluded that in an analysis of data from a population-based colonoscopy registry, they found index large SP or index STSA with no index HRA increased risk of metachronous large SPs but not metachronous HRA. HRA and synchronous SPs at index colonoscopy significantly increased risk of metachronous HRA. Individuals with HRA and synchronous could therefore benefit from close surveillance.

Joseph C. Anderson, MD, the lead author of the study, said, “We found that while people with serrated polyps were at increased risk for future serrated polyps, they were not at risk for future high-risk adenomas. Not surprisingly, people with high-risk adenomas were at increased risk for high-risk adenomas. However, we made a novel observation that people with both serrated polyps and high-risk adenomas had a risk for future high-risk adenomas that was substantially higher than even people with high-risk adenomas alone.” The study was published on September 16, 2017, in the journal Gastroenterology.

Related Links:
Dartmouth-Hitchcock Medical Center


Platinum Member
ADAMTS-13 Protease Activity Test
ATS-13 Activity Assay
Verification Panels for Assay Development & QC
Seroconversion Panels
Complement 3 (C3) Test
GPP-100 C3 Kit
Gold Member
High-Density Lipoprotein Containing Cholesterol Assay
HDL-c direct FS
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: QIP-MS could predict and detect myeloma relapse earlier compared to currently used techniques (Photo courtesy of Adobe Stock)

Mass Spectrometry-Based Monitoring Technique to Predict and Identify Early Myeloma Relapse

Myeloma, a type of cancer that affects the bone marrow, is currently incurable, though many patients can live for over 10 years after diagnosis. However, around 1 in 5 individuals with myeloma have a high-risk... Read more

Immunology

view channel
Image: The cancer stem cell test can accurately choose more effective treatments (Photo courtesy of University of Cincinnati)

Stem Cell Test Predicts Treatment Outcome for Patients with Platinum-Resistant Ovarian Cancer

Epithelial ovarian cancer frequently responds to chemotherapy initially, but eventually, the tumor develops resistance to the therapy, leading to regrowth. This resistance is partially due to the activation... Read more

Technology

view channel
Image: Ziyang Wang and Shengxi Huang have developed a tool that enables precise insights into viral proteins and brain disease markers (Photo courtesy of Jeff Fitlow/Rice University)

Light Signature Algorithm to Enable Faster and More Precise Medical Diagnoses

Every material or molecule interacts with light in a unique way, creating a distinct pattern, much like a fingerprint. Optical spectroscopy, which involves shining a laser on a material and observing how... Read more

Industry

view channel
Image: The collaboration aims to leverage Oxford Nanopore\'s sequencing platform and Cepheid\'s GeneXpert system to advance the field of sequencing for infectious diseases (Photo courtesy of Cepheid)

Cepheid and Oxford Nanopore Technologies Partner on Advancing Automated Sequencing-Based Solutions

Cepheid (Sunnyvale, CA, USA), a leading molecular diagnostics company, and Oxford Nanopore Technologies (Oxford, UK), the company behind a new generation of sequencing-based molecular analysis technologies,... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.